Hepatitis B immunoglobulin
Phase 2Small molecule
GileadHepatitis B immunoglobulin is one of 77 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 2.
2
Indications
4
Total Trials
1
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
71 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1Vemlidy
GileadApproved
Viread
GileadApproved
PEG-Intron
Merck & Co.Phase 3
Emtriva
GileadApproved
Jardiance
Boehringer IngelheimApproved
Opdivo
Bristol-Myers SquibbPhase 2
Pegylated Interferon Alfa
Merck & Co.Phase 3
NA Therapy
GSKPhase 3
AHB-137
AAusper Biopharma Co., Ltd.
Phase 3
Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis2 trials
Hepatitis B1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hepatitis B immunoglobulin. EMBL-EBI & Wellcome Sanger Institute.
- [4]